Market closed
Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
350
Website
HALO Metrics
BasicAdvanced
$7.4B
17.50
$3.43
1.25
-
Price and volume
Market cap
$7.4B
Beta
1.25
52-week high
$66.00
52-week low
$38.88
Average daily volume
1.6M
Financial strength
Current ratio
7.803
Quick ratio
6.503
Long term debt to equity
420.386
Total debt to equity
422.324
Interest coverage (TTM)
30.48%
Management effectiveness
Return on assets (TTM)
18.16%
Return on equity (TTM)
198.42%
Valuation
Price to earnings (TTM)
17.501
Price to revenue (TTM)
7.499
Price to book
20.32
Price to tangible book (TTM)
-16.25
Price to free cash flow (TTM)
16.255
Growth
Revenue change (TTM)
22.44%
Earnings per share change (TTM)
63.33%
3-year revenue growth (CAGR)
31.82%
3-year earnings per share growth (CAGR)
7.77%
What the Analysts think about HALO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
HALO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HALO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $7.4B as of May 03, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 17.5 as of May 03, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.